Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$79.33 USD

79.33
5,728,877

-2.48 (-3.03%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $79.34 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring

by Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.

    FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)

    by Zacks Equity Research

    Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.

      Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

      by Zacks Equity Research

      Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

        FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC

        by Zacks Equity Research

        AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.

          Merck's Keytruda Reduces Death Risk in Melanoma Patients

          by Zacks Equity Research

          Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.

            Spectrum Pharma Stock Up on Positive Lung Cancer Study Data

            by Zacks Equity Research

            Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.

              Ionis (IONS) Clinches Licensing Agreement with AstraZeneca

              by Zacks Equity Research

              Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.

                Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy

                by Zacks Equity Research

                Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.

                  Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus

                  by Zacks Equity Research

                  Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study

                    Pfizer's Lung Cancer Candidate Gets FDA's Priority Review

                    by Zacks Equity Research

                    Pfizer's (PFE) regulatory application for dacomitinib gets accepted in the United States under priority review for non-small cell lung cancer. The EU also accepts the filing for the same indication.

                      Kinjel Shah headshot

                      3 Emerging Technologies Set to Transform the Pharma World

                      by Kinjel Shah

                      Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by saving time as well as cost.

                        Allergan's Vraylar Meets Endpoints in Bipolar I Phase III

                        by Zacks Equity Research

                        Allergan (AGN) along with partner Gedeon Richter posts positive top-line results from the third pivotal study, analyzing label expansion of the schizophrenia drug Vraylar to cure bipolar I depression.

                          AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use

                          by Zacks Equity Research

                          AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States and EU, respectively.

                            Aeglea Initiates Lung Cancer Combination Study With Keytruda

                            by Zacks Equity Research

                            Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.

                              Acorda Files Parkinson's Drug Marketing Application in EU

                              by Zacks Equity Research

                              Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.

                                Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug

                                by Zacks Equity Research

                                Clovis' (CLVS) ovarian cancer drug, Rubraca, gets positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

                                  Pharma Stock Roundup: ABBV's Rova-T Disappoints, J&J Unit Gets Buyout Offer

                                  by Zacks Equity Research

                                  AbbVie's key lung cancer candidate, Rova-T falls short in a phase II study, J&J gets buyout offer for its LifeScan unit from private firm, Platinum Equity.

                                    Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus

                                    by Zacks Equity Research

                                    Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.

                                      Inovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat

                                      by Zacks Equity Research

                                      Inovio (INO) reports a narrower-than-expected loss in Q4. Moreover, revenues also beat estimates during the period and increased year over year.

                                        Kinjel Shah headshot

                                        Cancer Space Takes Giant Strides: Are Patients Benefiting?

                                        by Kinjel Shah

                                        The new cancer treatments are probably not doing enough to cure patients or help them live longer or better.

                                          AstraZeneca's Final Data From Key Lung Cancer Study Delayed

                                          by Zacks Equity Research

                                          AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.

                                            Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

                                            by Zacks Equity Research

                                            Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

                                              Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM's Acne Candidate Fails

                                              by Zacks Equity Research

                                              Key announcements include the failure of Dermira's (DERM) acne candidate in two pivotal late-stage studies and Merck's oncology collaboration with Japan's Eisai.

                                                AstraZeneca's Forxiga Label Expansion Filing Accepted in EU

                                                by Zacks Equity Research

                                                AstraZeneca's (AZN) submission for label expansion of diabetes drug Forxiga accepted by the European Medicines Agency.

                                                  Are Alzheimer's-Focused Stocks Set for a Financial Windfall?

                                                  by Zacks Equity Research

                                                  Launch of the blood tests will help companies focused on developing preventive treatments make billions.